NIH unable to comply with FOIA on its ivermectin recommendation

NIH unable to comply with FOIA on its ivermectin recommendation

The NIH updated its recommendation on the use of ivermectin in COVID-19 on January 14. The updated recommendation stated:

“There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19.”

However, there was uncertainty as to whether a vote of the Panel was held on this recommendation. This type of recommendation was not a “rated” recommendation. As per the January 14 update of the Guidelines:

“To be included in the Guidelines, a recommendation must be endorsed by a majority of Panel members. Updates to existing sections that do not affect the rated recommendations are approved by Panel co-chairs without a Panel vote.”

We submitted a Freedom of Information Act (FOIA) request to the NIH to ask if there had been a vote on the recommendation. In their response, the Panel was unable to respond to that request stating:

“Please be advised that the FOIA is not intended to answer questions…”

The NIH also was not able to answer that question when it was made by email. In its response, the section on Controlled Correspondence and Public Inquir...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee